Immunotherapy in adult acute leukemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute myeloid leukemia (AML) treatment has seen limited progress.
• Acute lymphoblastic leukemia (ALL) has experienced some therapeutic advancements.
• Emerging immunotherapies are becoming available for acute leukemias.

Purpose of the Study:

• To review novel immunotherapy approaches for acute leukemia.
• To focus on cell-based immunotherapies and molecules utilizing host cells.
• To provide an overview of currently available treatments and clinical experiences.

Main Methods:

• Review of clinical trial data (Phase 1-3) for immunotherapies.
• Focus on antibody-drug conjugates, bispecific T-cell engagers (BiTEs), chimeric antigen receptor T cells (CAR-Ts), and immune checkpoint inhibitors (ICPIs).
• Inclusion of studies on both ALL and AML patients, with emphasis on ALL.

Main Results:

• Immunotherapies show promise, particularly for relapsed ALL.
• Clinical data from Phase 1-3 studies are presented for various immunotherapeutic agents.
• Studies on AML patients were included where available.

Conclusions:

• Novel immunotherapies represent a significant advancement in acute leukemia treatment.
• These approaches offer hope for patients with poor prognoses.
• Future developments may involve earlier integration of these therapies to improve outcomes.